Comparative Pharmacology
Head-to-head clinical analysis: BAYCOL versus ROSUVASTATIN ZINC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAYCOL versus ROSUVASTATIN ZINC.
BAYCOL vs ROSUVASTATIN ZINC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cerivastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing hepatic cholesterol production and increasing LDL receptor expression.
Rosuvastatin zinc is a HMG-CoA reductase inhibitor that competitively inhibits the conversion of HMG-CoA to mevalonate, reducing hepatic cholesterol synthesis, increasing LDL receptor expression, and lowering plasma LDL-C and triglycerides.
Cervastatin 0.4 mg orally once daily in the evening, with or without food.
Oral, 5-40 mg once daily. Starting dose 10-20 mg; titrate based on LDL-C response. Maximum dose 40 mg.
None Documented
None Documented
2-4 hours (terminal elimination half-life); clinical context: supports twice-daily dosing
Terminal elimination half-life is approximately 19 hours (range 13–20 hours). This supports once-daily dosing, with steady-state reached within 5 days.
Renal: ~70% (mostly as unchanged drug); fecal: ~15%
Primarily biliary/fecal: approximately 90% of the dose is eliminated unchanged in feces via biliary secretion. Renal excretion accounts for about 10%, mainly as unchanged drug.
Category C
Category D/X
Statin
Statin